James Peyer - Jun 10, 2022 Form 4/A - Amendment Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Director, 10%+ Owner
Signature
/s/ Sarah Field, Attorney-in-Fact
Stock symbol
SNSE
Transactions as of
Jun 10, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
8/1/2022, 05:45 PM
Date Of Original Report
Jun 14, 2022
Previous filing
Jun 10, 2022
Next filing
Jul 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNSE Restricted Stock Unit Grant Award $0 +4.47K +0.09% $0.00 5.24M Jun 10, 2022 See Footnote F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (right to buy) Award $0 +14.6K $0.00 14.6K Jun 10, 2022 Common Stock 14.6K $2.05 See Footnote F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
F2 These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
F3 The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
F4 Amendment filed solely to correct the number of shares owned.